JP2009510142A - 急性および慢性肺障害の処置のための可溶性グアニル酸シクラーゼ活性化剤の使用 - Google Patents
急性および慢性肺障害の処置のための可溶性グアニル酸シクラーゼ活性化剤の使用 Download PDFInfo
- Publication number
- JP2009510142A JP2009510142A JP2008533900A JP2008533900A JP2009510142A JP 2009510142 A JP2009510142 A JP 2009510142A JP 2008533900 A JP2008533900 A JP 2008533900A JP 2008533900 A JP2008533900 A JP 2008533900A JP 2009510142 A JP2009510142 A JP 2009510142A
- Authority
- JP
- Japan
- Prior art keywords
- acute
- treatment
- medicament
- copd
- guanylate cyclase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FTQHGWIXJSSWOY-UHFFFAOYSA-N COC(Nc1c(N)nc(-c2n[n](Cc(cccc3)c3F)c3ncccc23)nc1N)=O Chemical compound COC(Nc1c(N)nc(-c2n[n](Cc(cccc3)c3F)c3ncccc23)nc1N)=O FTQHGWIXJSSWOY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
本発明の化合物は、これらの投与経路のために、適する投与形で投与できる。
低酸素症モデル:
実験的肺高血圧症のモデルで本発明の化合物(IV)の効果を調べる方法は、記載された(Dumitrascu R, Weissmann N, Ghofrani HA, Beuerlein K, Schmidt HHHW, Stasch JP, Gnoth MJ, Seeger W, Grimminger F, Schermuly RT, Activation of soluble guanylate cyclase reverses lung vascular remodeling and pulmonary hypertension evoked by hypoxia in mice, Circulation 2006, 113: 286-295)。この目的で、オスのC57B1/6Jマウス(Charles River Laboratories)を、7または10日間にわたり低酸素(10%O2)に付した。対照動物を正常酸素環境で維持した。10日間にわたり、飼料中の300ppmの化合物(IV)でマウスを処置した。試験終了時に、マウスを殺し、肺を単離した。上記の刊行物にある通りに、組織学的処理および評価を実施した。低酸素対照動物と比較して、肺血管の非筋肉化および部分的筋肉化の割合は、化合物(IV)で処置したマウスにおいて有意に少ない(図1)。
Claims (7)
- 式(I−VI)の化合物およびそれらの塩、水和物、塩の水和物の、呼吸促迫症候群[急性肺損傷(ALI)、急性呼吸促迫症候群(ARDS)]などの急性および慢性肺障害の処置用およびCOPDの処置用の薬剤を製造するための使用。
- 薬剤が経口投与形のために使用される、請求項1および請求項2のいずれかに記載の使用。
- 薬剤が静脈内に与えられるものである、請求項1および請求項2のいずれかに記載の使用。
- 薬剤が予防的に使用される、請求項1および請求項2のいずれかに記載の使用。
- 請求項1に記載の少なくとも1種の物質を含む、肺高血圧の処置用の医薬組成物。
- 請求項1に記載の少なくとも1種の物質を含む、呼吸促迫症候群[急性肺損傷(ALI)、急性呼吸促迫症候群(ARDS)]などの急性および慢性肺障害の処置用およびCOPDの処置用の医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005047946A DE102005047946A1 (de) | 2005-10-06 | 2005-10-06 | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten |
PCT/EP2006/009264 WO2007039155A2 (de) | 2005-10-06 | 2006-09-23 | Verwendung von aktivatoren der löslichen guanylatzyklase zur behandlung von akuten und chronischen lungenkrankheiten |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2009510142A true JP2009510142A (ja) | 2009-03-12 |
Family
ID=37106347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008533900A Pending JP2009510142A (ja) | 2005-10-06 | 2006-09-23 | 急性および慢性肺障害の処置のための可溶性グアニル酸シクラーゼ活性化剤の使用 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20090286781A1 (ja) |
EP (1) | EP1945218A2 (ja) |
JP (1) | JP2009510142A (ja) |
KR (1) | KR20080065283A (ja) |
CN (1) | CN101282727A (ja) |
AU (1) | AU2006299149A1 (ja) |
BR (1) | BRPI0616921A2 (ja) |
CA (1) | CA2624716A1 (ja) |
DE (1) | DE102005047946A1 (ja) |
IL (1) | IL190619A0 (ja) |
RU (1) | RU2417083C2 (ja) |
WO (1) | WO2007039155A2 (ja) |
ZA (1) | ZA200802874B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013518851A (ja) * | 2010-02-05 | 2013-05-23 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | sGC刺激剤又はsGC活性化剤単独及びPDE5阻害剤と組合せた嚢胞性線維症処置 |
JP2015522597A (ja) * | 2012-07-20 | 2015-08-06 | バイエル ファーマ アクチエンゲゼルシャフト | 新規の5−アミノテトラヒドロキノリン−2−カルボン酸およびその使用 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE202008014557U1 (de) | 2008-10-27 | 2009-03-12 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Therapeutische Verwendung |
CA2803688A1 (en) * | 2010-06-25 | 2011-12-29 | Bayer Intellectual Property Gmbh | Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes |
CN102485724B (zh) * | 2010-12-06 | 2015-08-12 | 中国人民解放军军事医学科学院毒物药物研究所 | 取代噻吩基吡唑并吡啶类化合物及其医药用途 |
ES2583086T3 (es) * | 2011-04-21 | 2016-09-19 | Bayer Intellectual Property Gmbh | Pirazolopiridinas sustituidas con fluoroalquilo y su uso |
US10265314B2 (en) | 2013-07-25 | 2019-04-23 | Bayer Pharma Aktiengesellschaft | SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis |
CN108785309A (zh) * | 2018-04-23 | 2018-11-13 | 周静 | 化合物在制备治疗慢性肺病的药物中的用途 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002521483A (ja) * | 1998-07-29 | 2002-07-16 | バイエル アクチェンゲゼルシャフト | 6−員複素環式環と縮合した置換ピラゾール誘導体 |
WO2003095451A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Healthcare Ag | Carbamat-substituierte pyrazolopyridine |
GB2395431A (en) * | 2002-11-20 | 2004-05-26 | Northwick Park Inst For Medica | Combination of a metal carbonyl compound and a guanylate cyclase stimulant or stabilizer for the therapeutic delivery of carbon monoxide |
WO2005013691A1 (en) * | 2003-08-04 | 2005-02-17 | Hemocorm Limited | Use of boranocarbonates for the therapeutic delivery of carbon monoxide |
WO2005042022A2 (en) * | 2003-10-29 | 2005-05-12 | Pfizer Limited | Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist |
WO2005046725A1 (de) * | 2003-11-06 | 2005-05-26 | Bayer Healthcare Ag | Neue kombination enthaltend einen stimulator der löslichen guanylatcyclase und einen lipidsenker |
JP2005524695A (ja) * | 2002-04-26 | 2005-08-18 | アルタナ ファルマ アクチエンゲゼルシャフト | 呼吸機能不全を治療するためのグアニル酸シクラーゼ活性化剤の新規の使用 |
WO2005077005A2 (en) * | 2004-02-04 | 2005-08-25 | The General Hospital Corporation | Enhancing the effectiveness of an inhaled therapeutic gas |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19943635A1 (de) * | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
AR031176A1 (es) * | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
EP1663239A4 (en) * | 2003-09-10 | 2008-07-23 | Cedars Sinai Medical Center | KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER |
EP1799210A1 (en) * | 2004-10-05 | 2007-06-27 | Bayer HealthCare AG | A guanylate cyclase stimulator and nitric oxide for treating bronchoconstriction and pulmonary vasconstriction |
-
2005
- 2005-10-06 DE DE102005047946A patent/DE102005047946A1/de not_active Withdrawn
-
2006
- 2006-09-23 KR KR1020087010682A patent/KR20080065283A/ko not_active Application Discontinuation
- 2006-09-23 AU AU2006299149A patent/AU2006299149A1/en not_active Abandoned
- 2006-09-23 WO PCT/EP2006/009264 patent/WO2007039155A2/de active Application Filing
- 2006-09-23 EP EP06777198A patent/EP1945218A2/de not_active Withdrawn
- 2006-09-23 BR BRPI0616921-0A patent/BRPI0616921A2/pt not_active IP Right Cessation
- 2006-09-23 RU RU2008117303/15A patent/RU2417083C2/ru not_active IP Right Cessation
- 2006-09-23 CN CNA2006800373890A patent/CN101282727A/zh active Pending
- 2006-09-23 JP JP2008533900A patent/JP2009510142A/ja active Pending
- 2006-09-23 US US12/083,121 patent/US20090286781A1/en not_active Abandoned
- 2006-09-23 CA CA002624716A patent/CA2624716A1/en not_active Abandoned
-
2008
- 2008-04-02 ZA ZA200802874A patent/ZA200802874B/xx unknown
- 2008-04-03 IL IL190619A patent/IL190619A0/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002521483A (ja) * | 1998-07-29 | 2002-07-16 | バイエル アクチェンゲゼルシャフト | 6−員複素環式環と縮合した置換ピラゾール誘導体 |
JP2005524695A (ja) * | 2002-04-26 | 2005-08-18 | アルタナ ファルマ アクチエンゲゼルシャフト | 呼吸機能不全を治療するためのグアニル酸シクラーゼ活性化剤の新規の使用 |
WO2003095451A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Healthcare Ag | Carbamat-substituierte pyrazolopyridine |
GB2395431A (en) * | 2002-11-20 | 2004-05-26 | Northwick Park Inst For Medica | Combination of a metal carbonyl compound and a guanylate cyclase stimulant or stabilizer for the therapeutic delivery of carbon monoxide |
WO2005013691A1 (en) * | 2003-08-04 | 2005-02-17 | Hemocorm Limited | Use of boranocarbonates for the therapeutic delivery of carbon monoxide |
WO2005042022A2 (en) * | 2003-10-29 | 2005-05-12 | Pfizer Limited | Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist |
WO2005046725A1 (de) * | 2003-11-06 | 2005-05-26 | Bayer Healthcare Ag | Neue kombination enthaltend einen stimulator der löslichen guanylatcyclase und einen lipidsenker |
WO2005077005A2 (en) * | 2004-02-04 | 2005-08-25 | The General Hospital Corporation | Enhancing the effectiveness of an inhaled therapeutic gas |
Non-Patent Citations (2)
Title |
---|
JPN6011023226; EVGENOV,O.V. et al.: 'Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary' Circulation Vol. 110, No. 15, 20041012, p.2253-2259 * |
JPN6012021365; Deruelle, Philippe et al.: 'Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in t' American Journal of Physiology Vol. 288, 200504, p. L727-L733 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013518851A (ja) * | 2010-02-05 | 2013-05-23 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | sGC刺激剤又はsGC活性化剤単独及びPDE5阻害剤と組合せた嚢胞性線維症処置 |
JP2016155857A (ja) * | 2010-02-05 | 2016-09-01 | アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 嚢胞性線維症処置用のsGC刺激剤又はsGC活性化剤単独及びPDE5阻害剤との組み合わせ物 |
JP2015522597A (ja) * | 2012-07-20 | 2015-08-06 | バイエル ファーマ アクチエンゲゼルシャフト | 新規の5−アミノテトラヒドロキノリン−2−カルボン酸およびその使用 |
Also Published As
Publication number | Publication date |
---|---|
RU2417083C2 (ru) | 2011-04-27 |
AU2006299149A1 (en) | 2007-04-12 |
WO2007039155A3 (de) | 2007-10-11 |
CA2624716A1 (en) | 2007-04-12 |
ZA200802874B (en) | 2009-09-30 |
WO2007039155A2 (de) | 2007-04-12 |
IL190619A0 (en) | 2008-12-29 |
KR20080065283A (ko) | 2008-07-11 |
EP1945218A2 (de) | 2008-07-23 |
BRPI0616921A2 (pt) | 2011-07-05 |
US20090286781A1 (en) | 2009-11-19 |
CN101282727A (zh) | 2008-10-08 |
DE102005047946A1 (de) | 2007-05-03 |
RU2008117303A (ru) | 2009-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009510142A (ja) | 急性および慢性肺障害の処置のための可溶性グアニル酸シクラーゼ活性化剤の使用 | |
RU2199322C2 (ru) | Новое применение будезонида и формотерола | |
US5728705A (en) | Method of inducing vasorelaxation to treat pulmonary hypertension | |
JP2002539154A (ja) | ベンゾインデンプロスタグランジンの吸入送達法 | |
KR20080005601A (ko) | Pde4 억제제 로플루밀라스트와 테트라히드로비오프테린유도체의 조합 | |
RU2685706C2 (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
JPWO2013081154A1 (ja) | キナーゼ阻害剤の副作用低減剤 | |
JP2009501737A (ja) | レイノー現象の処置のための可溶性グアニル酸シクラーゼ活性化剤の使用 | |
CN110087653A (zh) | 用于治疗肺高血压的组合疗法 | |
US20180110774A1 (en) | Compositions and methods for treatment of pulmonary hypertension | |
US20120003325A1 (en) | Use of helium-oxygen gas mixtures for treating pulmonary arterial hypertension | |
JP2009500365A (ja) | 再灌流障害を処置するための可溶性グアニル酸シクラーゼ活性化剤の使用 | |
US20070287689A1 (en) | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases | |
ZA200602536B (en) | Use of BH4 for the treatment of respiratory diseases | |
US20220362222A1 (en) | Once daily formulations of tacrolimus | |
US7485642B2 (en) | Method for treating septic shock | |
AU2021382051A1 (en) | Imatinib formulations, manufacture, and uses thereof | |
JP2024506840A (ja) | 化学ガス曝露を処置する方法 | |
CN117098557A (zh) | 伊马替尼调配物、其制备和用途 | |
CN116270657A (zh) | 一种预防和/或治疗胃肠道疾病的药物组合物及其用途 | |
De Jager et al. | Sildenafil in the treatment of pulmonary hypertension in the neonate: paediatrics | |
US20040157772A1 (en) | Use of a gatran for the manufacture of a medicament of the treatment of pulmonary fibrosis | |
AU2002305989A1 (en) | The use of a gatran for the manufacture of a medicament for the treatment of pulmonary fibrosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090918 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20090918 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120508 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120808 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120815 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130108 |